RSDL is a patented, broad spectrum topical skin decontamination product intended to neutralize or remove CW
agents and T-2 toxin from the skin.

GF (Cyclohexyl SARIN)
VX (Nerve Agent)
HD (Mustard)
• T-2 toxin

RSDLwas originally developed by the Canadian Department of National Defence (DND), RSDL has since been adopted by several military services around the world. The U.S. FDA issued 510(k) clearance for RSDL in March of 2003 and has cleared the use of RSDL in 21 and 42 mL packets.

RSDL received Milestone C approval from the Joint Program Executive Office for Chemical Biological Defense (JPEO-CBD). The US Food and Drug Administration (FDA) issued 510(k) clearance for RSDL in March of 2003. The U.S. DoD began final configuration testing on the product in November of 2003 and authorized the sale of RSDL to first responder organizations in September of 2004. In September 2006, RSDL was awarded Safety Act certification by the U.S. Department of Homeland Security (DHS), which extends certain liability protections to the Company and its suppliers and customers (whether public or private) in the event RSDL is used in response to a terrorist incident. In September 2007, the U.S. DoD transferred the 510(k) for RSDL to the Company.

Main Product Features RSDL Advantages
Reactive Decontaminant Neutralizes or removes CW agents and T-2 toxin from the skin, rendering them non-toxic. Complete neutralization ensures no off-gassing of toxic CW agents
Individual Packets Easy-to-use, tear open packets tested for seal integrity
Liquid Texture Feel where the lotion has been applied, even with eyes closed
Tested Technology RSDL was rigorously tested by the US DoD and the Canadian DND

RSDL has been cleared for marketing by the Food and Drug Administration as a medical device for the decontamination of skin exposed to chemical agents and certain biological toxins. The US Army was the sponsor of this application, and the approval is held by the Office of the Army Surgeon General.

RSDL is a topical decontamination solution that has been tested and shown to reduce toxic effects from exposure to chemical warfare agents (VX and HD) and T-2 toxin. RSDL contains Dekon 139 and a small amount of 2,3 butadiene monoxime (DAM). These compounds are dissolved in a solvent composed of polyethylene glycol monomethyl ether (MPEG) and water. This solvent system is particularly important as it promotes the decontamination reaction by actively desorbing, retaining and sequestering the chemical agent, while the active ingredient (Dekon 139) chemically reacts with, and rapidly neutralizes the vesicant chemical or the organophosphorous nerve agent.This reaction starts immediately and neutralization is usually complete within two minutes.

Precautions & Warnings
For external use only. Contact with eyes and mucous membranes should be avoided. RSDL should not be used for wound decontamination because its effects on wounds and effects resulting from its absorption through the wound have not been studied.

Avoid extended contact with the skin. In emergency conditions, does not require immediate removal from the skin and can be left on under protective clothing, but should be rinsed as soon as it is safe to do so. One of the ingredients (DAM) is absorbed through the skin. RSDL has not been tested in humans using amounts required for decontamination. Intravenous injections of DAM have been shown to cause serious systemic toxicity up to and including a transient comatose state (unconsciousness). There have been no instances of death. Topical adverse effects are not expected to be nearly as severe as with intravenous administration. Pending further studies, do not use RSDL for whole body decontamination or use excessive quantities.

The RSDL vehicle (MPEG) when combined with some commonly used decontamination materiels, i.e., solid powdered HTH (calcium hypochlorite) or solid powdered Super Tropical Bleach, causes spontaneous combustion. Should RSDL be used on the same decontamination line as either of these products, care must be taken to keep them apart. Do not discard RSDL packaging and sponge into containers that contain or have contained HTH (high test hypochlorite) or Super Tropical Bleach.

DAM has been shown to cross the placental barrier but teratogenicity studies have not been performed ; thus RSDL should only be used during pregnancy when absolutely necessary. RSDL has been shown to be non-mutagenic and inhalation and reproductive studies in rats have shown RSDL not to cause any ill effects.

The full strength solution is applied on body surfaces after exposure to chemical warfare agents (RSDL should not be used before exposure since its effectiveness following prophylactic use has not been evaluated). Generally, one 21 mL packet is sufficient to decontaminate hands, neck, and face. The packaging and sponge should be discarded after single use.

How Supplied:
The FDA has cleared the use of RSDL in 21 and 42 mL packets. Each ml of solution contains 1.25 M or 173 mg of Dekon 139 and 35-43 mg of DAM in an MPEG and water solvent.

For Additional Information, Please Consult the Material Safety Data Sheet.



link to ftp